<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke - Sandercock, PAG - 2017 | Cochrane Library</title> <meta content="Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke - Sandercock, PAG - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000119.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke - Sandercock, PAG - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000119.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000119.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke" name="citation_title"/> <meta content="Peter AG Sandercock" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="peter.sandercock@ed.ac.uk" name="citation_author_email"/> <meta content="Tze Shin Leong" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD000119.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/04/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000119.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000119.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000119.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Anticoagulants [*therapeutic use]; Brain Ischemia [drug therapy]; Cause of Death; Fibrinolytic Agents [*therapeutic use]; Hemorrhage [chemically induced, epidemiology]; Heparin [therapeutic use]; Heparin, Low‐Molecular‐Weight [*therapeutic use]; Heparinoids [*therapeutic use]; Pulmonary Embolism [epidemiology]; Randomized Controlled Trials as Topic; Stroke [*drug therapy, mortality]; Venous Thrombosis [epidemiology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000119.pub4&amp;doi=10.1002/14651858.CD000119.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000119\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000119\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","fr","ta","ja","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000119.pub4",title:"Low\\u2010molecular\\u2010weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke",firstPublishedDate:"Apr 4, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000119.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000119.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000119.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000119.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000119.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000119.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000119.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000119.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000119.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000119.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5395 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000119.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/appendices#CD000119-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/table_n/CD000119StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/table_n/CD000119StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information#CD000119-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Peter AG Sandercock</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information#CD000119-cr-0003">Tze Shin Leong</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information/en#CD000119-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 April 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000119.pub4">https://doi.org/10.1002/14651858.CD000119.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000119-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000119-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000119-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000119-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000119-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000119-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000119-abs-0001" lang="en"> <section id="CD000119-sec-0001"> <h3 class="title" id="CD000119-sec-0001">Background</h3> <p>Low‐molecular‐weight heparins (LMWHs) and heparinoids are anticoagulants that may have more powerful antithrombotic effects than standard unfractionated heparin (UFH) but a lower risk of bleeding complications. This is an update of the original Cochrane Review of these agents, first published in 2001 and last updated in 2008. </p> </section> <section id="CD000119-sec-0002"> <h3 class="title" id="CD000119-sec-0002">Objectives</h3> <p>To determine whether antithrombotic therapy with LMWHs or heparinoids is associated with a reduction in the proportion of people who are dead or dependent for activities in daily living compared with UFH. </p> </section> <section id="CD000119-sec-0003"> <h3 class="title" id="CD000119-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (last searched February 2017), the Cochrane Central Register of Controlled Trials (CENTRAL: <i>the Cochrane Library</i> Issue 1, 2017), MEDLINE (1966 to February 2017), and Embase (1980 to February 2017). We also searched trials registers to February 2017: ClinicalTrials.gov, EU Clinical Trials Register, Stroke Trials Registry, ISRCTN Registry and the World Health Organization (WHO) International Clinical Trials Registry Platform. </p> </section> <section id="CD000119-sec-0004"> <h3 class="title" id="CD000119-sec-0004">Selection criteria</h3> <p>Unconfounded randomised trials comparing LMWH or heparinoids with standard UFH in people with acute ischaemic stroke, in which participants were recruited within 14 days of stroke onset. </p> </section> <section id="CD000119-sec-0005"> <h3 class="title" id="CD000119-sec-0005">Data collection and analysis</h3> <p>Two review authors independently chose studies for inclusion, assessed risk of bias and trial quality, extracted and analysed the data. Differences were resolved by discussion. </p> </section> <section id="CD000119-sec-0006"> <h3 class="title" id="CD000119-sec-0006">Main results</h3> <p>We included nine trials involving 3137 participants. We did not identify any new trials for inclusion in this updated review. None of the studies reported data on the primary outcome in sufficient detail to enable analysis for the review. Overall, there was a moderate risk of bias in the included studies. Compared with UFH, there was no evidence of an effect of LMWH or heparinoids on death from all causes during the treatment period (96/1616 allocated LMWH/heparinoid versus 78/1486 allocated UFH; odds ratio (OR) 1.06, 95% CI 0.78 to 1.47; 8 trials, 3102 participants, low quality evidence). LMWH or heparinoid were associated with a significant reduction in deep vein thrombosis (DVT) compared with UFH (OR 0.55, 95% CI 0.44 to 0.70, 7 trials, 2585 participants, low quality evidence). However, the number of the major clinical events such as pulmonary embolism (PE) and intracranial haemorrhage was too small to provide a reliable estimate of the effects. </p> </section> <section id="CD000119-sec-0007"> <h3 class="title" id="CD000119-sec-0007">Authors' conclusions</h3> <p>Treatment with a LMWH or heparinoid after acute ischaemic stroke appears to decrease the occurrence of DVT compared with standard UFH, but there are too few data to provide reliable information on their effects on other important outcomes, including functional outcome, death and intracranial haemorrhage. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000119-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000119-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000119-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000119-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000119-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000119-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000119-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000119-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000119-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/ta#CD000119-abs-0009">தமிழ்</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000119-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000119-abs-0004" lang="en"> <h3>Which types of blood‐thinning drugs (anticoagulants) are best to prevent blood clots in people soon after stroke? </h3> <p><b>Review question</b> </p> <p>This review aimed to find out which type of blood‐thinning drug works best for preventing blood clots in people who have recently had a stroke due to blockage of an artery in the brain. </p> <p><b>Background</b> </p> <p>Stroke is a common and disabling disease. Sudden blockage of an artery to the brain, often caused by a blood clot, is the cause of the most common type of stroke. This type is called an ischaemic stroke. Anticoagulants (blood‐thinning drugs), are widely used in people with stroke. As stroke is a medical emergency, and medicines given in an emergency need to reach the bloodstream quickly, these are given by injection. Injectable anticoagulants that have been tested in stroke are unfractionated heparin (UFH), low‐molecular‐weight heparins (LMWH), and heparinoids. These agents may help clear blocked arteries, prevent re‐blockage, and prevent clots forming in leg veins (deep vein thrombosis, DVT) after an ischaemic stroke and so might prevent fatal or disabling complications of stroke and improve the chance of a good recovery. However, they can also cause harmful bleeding complications that can offset any benefits. </p> <p><b>Search date</b> </p> <p>The search was updated to February 2017.</p> <p><b>Study characteristics</b> </p> <p>We looked for randomised controlled trials in people with recent onset of stroke symptoms that compared LMWH or heparinoids with UFH. </p> <p><b>Key results</b> </p> <p>We found nine trials involving 3137 participants; overall these trials had a moderate risk of bias (this means that the results are likely to be less credible than if the risk of bias was low). No new trials were included in this updated review. None of the studies reported reliable information on disability or recovery after stroke. Compared with UFH, there was no evidence of an effect of LMWH or heparinoids on death from all causes during the treatment period (quality of the evidence was low). Although LMWH or heparinoid were associated with significantly fewer clots in leg veins (DVT) than UFH, the number of major events such as when a blood clot becomes lodged in an artery in the lung (pulmonary embolism) and bleeding inside the skull (intracranial haemorrhages) was too small to know whether the harms outweighed the benefits. For people with ischaemic stroke who need immediate treatment with anticoagulants, evidence from the included clinical trials did not provide reliable evidence on the balance of risk and benefit for each type of heparin. Additional large scale research would be needed to resolve this uncertainty. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, there was a moderate risk of bias in the included studies. Using GRADE criteria we found that evidence quality was low overall. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000119-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000119-sec-0094"></div> <h3 class="title" id="CD000119-sec-0095">Implications for practice</h3> <section id="CD000119-sec-0095"> <p>For clinicians who, despite the lack of evidence of overall benefit from routine anticoagulants in people with acute ischaemic stroke, still wish to use some form of anticoagulant regimen in selected people with acute ischaemic stroke: </p> <p> <ul id="CD000119-list-0006"> <li> <p>the criteria to identify those few people that might benefit from the unfractionated heparin (UFH), low‐molecular‐weight heparin (LMWH) or heparinoid regimens tested in these trials have not been defined; </p> </li> <li> <p>LMWH and heparinoids appear to be more effective at preventing deep venous thrombosis (DVT) ‐ and possibly also pulmonary embolism (PE) ‐ than UFH. However, their safety, compared with UFH, has not reliably been established in people with stroke. </p> </li> </ul> </p> </section> <h3 class="title" id="CD000119-sec-0096">Implications for research</h3> <section id="CD000119-sec-0096"> <p>It may well be that other antithrombotic agents, such as aspirin, will prove to be the antithrombotic agent with the most favourable balance of risk and benefit for use in people with acute ischaemic stroke. Further very large‐scale trials may be worthwhile comparing: </p> <p> <ul id="CD000119-list-0007"> <li> <p>aspirin alone with aspirin plus low‐dose LMWH (or heparinoid) in individuals at particularly high risk of DVT and PE; and </p> </li> <li> <p>a more aggressive LMWH (or heparinoid) regimen with UFH and with aspirin only in certain categories of people, for example those with a cardiac source of emboli. These trials should measure disability and recurrent stroke as well as venous thromboembolism and major haemorrhages. </p> </li> </ul> </p> <p>Given the lack of evidence for the routine use of any anticoagulant regimen in acute ischaemic stroke and the evidence in favour of using aspirin, further trials comparing only heparinoids or LMWH with UFH would be hard to justify. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000119-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000119-sec-0029"></div> <div class="table" id="CD000119-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Low‐molecular‐weight heparins or heparinoids compared with unfractionated heparin for acute ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐molecular‐weight heparins (LMWH) or heparinoids compared with unfractionated heparin (UFH) for acute ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute ischaemic stroke<br/> <b>Setting:</b> patients admitted to hospital with stroke of sufficient severity to cause immobility<br/> <b>Intervention:</b> LMWH/heparinoids<br/> <b>Comparison:</b> UFH </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with UFH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH/heparinoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Death from all causes during treatment</b> (range 6 days to 16 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 1.06<br/> (0.78 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3102<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/> (72 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000<br/> (105 to 180) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Death from all causes during follow up</b> (range 2 weeks to 12 weeks) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.98<br/> (0.79 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3102<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/> (187 to 263) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/> (209 to 292) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Deep vein thrombosis during treatment period</b> (range 6 days to 16 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.55<br/> (0.44 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2585<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000⁶</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000<br/> (93 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (105 to 158) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Pulmonary embolism during treatment period</b> (range 6 days to 16 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.57<br/> (0.23 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1250<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ⁷ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 7) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/> (6 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period</b> (range 6 days to 16 days)⁹ </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.73<br/> (0.35 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3102<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ⁸ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (4 to 18) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>RCT</b> : randomised controlled trial; <b>LWMH</b> : low‐molecular‐weight heparin; <b>UFH</b>: unfractionated heparin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ There were unclear risk of selection bias in <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a>, <a href="./references#CD000119-bbs2-0001" title="DumasR , WoitinasF , KutnowskiM , NikolicI , BerberichR , AbedinpourF , et al. A multi‐centre double blind randomized study to compare the safety and efficacy of once‐daily ORG 10172 and twice‐daily low‐dose heparin in preventing deep‐vein thrombosis in patients with acute ischaemic stroke. Age and Ageing1994;23(6):512‐6. HagelukenC , EgbertsJ , StiekemaJ . A multi‐centre, assessor‐blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non‐haemorrhagic stroke of recent onset (protocol 87038). Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands1992. ">Dumas 1994</a>, <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>, <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a>, <a href="./references#CD000119-bbs2-0008" title="MagnaniHN , EgbertsJFM . A preliminary report of a multi‐centre, assessor‐blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004‐010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands1992. TurpieAGG . Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis1992;22(2):92‐8. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1991;65:753. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A low‐molecular‐weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine1992;117(5):353‐7. ">Turpie 1992</a> and <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a>. <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a> and <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a> were single blinded studies; <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> was an open label study. Hence, making all these study high risk of performance and detection bias (downgraded 1 level). </p> <p>² Small number of deaths were recorded throughout studies (downgraded 1 level).</p> <p>³ Calculated based on control event rate from <a href="./references#CD000119-bbs2-0049" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569‐81. ">IST 1997</a> where based on the inclusion criteria, it was interpreted that people are of average risk (hence, they are classified as 'moderate risk population') of developing complications such as deep vein thrombosis (DVT), pulmonary embolism (PE), cranial haemorrhages etc. that resulted in death or disability. </p> <p>⁴ Calculated based on control event rate from <a href="./references#CD000119-bbs2-0042" title="DennisM , SandercockP , GrahamC , ForbesJ , Clots Trials Collaboration. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post‐stroke deep vein thrombosis and to estimate its cost‐effectiveness. Health Technology Assessment2015;19(76):1‐90. [DOI: 10.3310/hta19760] ">CLOTS3 2015</a> trial where based on the inclusion criteria, people are of high risk (hence they are classified as 'high risk population') of developing complications such as DVT, PE, cranial haemorrhages that resulted in death or disability. </p> <p>⁵ Methods of detection of detection of DVT were variable across the studies (downgraded 1 level). </p> <p>⁶ Calculated based on mean baseline risk from the studies of this Cochrane Review because <a href="./references#CD000119-bbs2-0049" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569‐81. ">IST 1997</a> did not include this outcome data. </p> <p>⁷ Small number of PEs across the studies.</p> <p>⁸ Small number of symptomatic intracranial haemorrhage across studies.</p> <p>⁹ High risk population not available as <a href="./references#CD000119-bbs2-0042" title="DennisM , SandercockP , GrahamC , ForbesJ , Clots Trials Collaboration. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post‐stroke deep vein thrombosis and to estimate its cost‐effectiveness. Health Technology Assessment2015;19(76):1‐90. [DOI: 10.3310/hta19760] ">CLOTS3 2015</a> trial did not include this outcome data. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000119-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000119-sec-0030"></div> <p>Low‐molecular‐weight heparins (LMWHs) and heparinoids are anticoagulants that may have more powerful antithrombotic effects than standard unfractionated heparin (UFH) but a lower risk of bleeding complications. This is an update of the Cochrane Review <i>Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke</i>, first published in 2001 (<a href="./references#CD000119-bbs2-0062" title="CounsellC , SandercockP . Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD000119] ">Counsell 2001</a>) and last updated in 2008 (<a href="./references#CD000119-bbs2-0064" title="SandercockPAG , CounsellC , TsengM‐C . Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD000119.pub3] ">Sandercock 2008</a>). </p> <section id="CD000119-sec-0031"> <h3 class="title" id="CD000119-sec-0031">Description of the condition</h3> <p>Worldwide, stroke is one of the most common causes of death and disability in both developed and developing countries (<a href="./references#CD000119-bbs2-0051" title="LozanoR , NaghaviM , ForemanK , LimS , ShibuyaK , AboyansV , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2095‐128. [DOI: 10.1016/S0140‐6736(12)61728‐0] ">Lozano 2012</a>). Four‐fifths of all strokes are caused by reduction in, or blockage of, blood flow in the artery supplying a particular part of brain; this type of stroke is called an ischaemic stroke (<a href="./references#CD000119-bbs2-0060" title="WarlowC , DennisM , VanGijnJ , SandercockP , BamfordJ , RothwellP , RinkelG , SudlowC , WardlawJ . Stroke: A practical Guide to Management .. 3. Oxford: Blackwell Science 2008, 2008. ">Warlow 2008</a>). A common cause of ischaemic stroke is a blood clot that developed in the heart or large arteries travelling through the circulation to block a brain blood vessel (<a href="./references#CD000119-bbs2-0038" title="CaplanLR . Caplan's stroke: a clinical approach. Basic Pathology, Anatomy, and Pathophysiology of Stroke. 4th Edition. Philadelphia: Saunders Elsevier, 2009:22. ">Caplan 2009</a>). </p> </section> <section id="CD000119-sec-0032"> <h3 class="title" id="CD000119-sec-0032">Description of the intervention</h3> <p>Anticoagulants act on different components of the coagulation system to reduce fibrin and thrombus formation (<a href="./references#CD000119-bbs2-0048" title="HolbrookA , SchulmanS , WittDM , VandvikPO , FishJ , KovacsMJ . Evidence‐based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141:52s. ">Holbrook 2012</a>). Some anticoagulants, such as Vitamin K antagonists, can only be given by mouth, have a slow onset of action, and so are not suitable for use as an emergency treatment in acute stroke where prompt onset of effect is needed and where difficulty swallowing from the stroke may preclude oral administration. The anticoagulant agents that have commonly been used in people with stroke that can be given parenterally and have a rapid onset of action are unfractionated heparin (UFH), low‐molecular‐weight heparins (LMWHs) and heparinoids (<a href="./references#CD000119-bbs2-0057" title="SandercockP , CounsellC , KaneEJ . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD000024] ">Sandercock 2015</a>). Standard UFH is a sulphated polysaccharide that affects the coagulation pathway by inhibition of Factor Xa and thrombin activity (<a href="./references#CD000119-bbs2-0040" title="ChoayJ . Structure and activity of heparin and its fragments: an overview. Seminars in Thrombosis and Hemostasis1989;15(4):359‐64. ">Choay 1989</a>; <a href="./references#CD000119-bbs2-0043" title="CruickshankMK , LevineMN , HirshJ , RobertsR , SiguenzaM . A standard heparin nomogram for the management of heparin therapy. Archives of Internal Medicine1991;151(2):333‐7. ">Cruickshank 1991</a>). LMWHs are smaller molecules derived from heparin and act predominantly to inhibit Factor Xa (<a href="./references#CD000119-bbs2-0039" title="CellaG , ScattoloN , LuzzatoG , StevanatoF , VioC , GirolamiA . Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf. Journal of Medicine1986;17(5‐6):331‐46. ">Cella 1986</a>; <a href="./references#CD000119-bbs2-0045" title="GordonDL , LinhardtR , AdamsHP . Low‐molecular‐weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clinical Neuropharmacology1990;13(6):522‐43. ">Gordon 1990</a>; <a href="./references#CD000119-bbs2-0061" title="WeitzJI . Low‐molecular‐weight heparins. New England Journal of Medicine1997;337(10):688. ">Weitz 1997</a>). Heparinoids are aminoglycans that inhibit thrombin activity via activation of the effect of heparin co‐factor 2 (<a href="./references#CD000119-bbs2-0058" title="ShorrAF , JacksonWL , ShernerJH , MooresLK . Differences between low‐molecular weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a meta‐analysis. Chest2008;133(1):149‐55. ">Shorr 2008</a>). LMWHs and heparinoids have better bioavailability and longer half‐life compared with UFH (<a href="./references#CD000119-bbs2-0044" title="GarciaDA , BaglinTP , WeitzJI , SamamaMM , American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141:e24S‐43S. ">Garcia 2012</a>; <a href="./references#CD000119-bbs2-0052" title="MeulemanDG . Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis1992;22(2):58‐65. ">Meuleman 1992</a>). </p> </section> <section id="CD000119-sec-0033"> <h3 class="title" id="CD000119-sec-0033">How the intervention might work</h3> <p>In people with ischaemic stroke who arrive in hospital within the first few hours of onset, anticoagulants may be used as an emergency treatment to help dissolve the blood clot blocking the cerebral vessel, or to prevent new blood clots forming in arteries or veins. Early use of anticoagulants in acute ischaemic stroke might therefore have several beneficial effects: to reduce cerebral damage from the initial stroke, prevent early recurrent ischaemic stroke, and prevent venous thromboembolic events (VTEs) (<a href="./references#CD000119-bbs2-0049" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569‐81. ">IST 1997</a>). VTEs include deep vein thrombosis (DVT, a blood clot lodging in a deep vein of the leg) and pulmonary embolism (PE, a blood clot lodging in an artery in the lungs). These actions of anticoagulants might reduce the chance of death from vascular causes, increase the chance of neurological recovery, and so improve the person's overall clinical outcome after acute ischaemic stroke (<a href="./references#CD000119-bbs2-0057" title="SandercockP , CounsellC , KaneEJ . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD000024] ">Sandercock 2015</a>). </p> </section> <section id="CD000119-sec-0034"> <h3 class="title" id="CD000119-sec-0034">Why it is important to do this review</h3> <p>Randomised trials comparing UFH, LMWH, and heparinoids with placebo have not provided any convincing evidence that these agents improve survival or functional outcome of people with acute ischaemic stroke (<a href="./references#CD000119-bbs2-0049" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569‐81. ">IST 1997</a>; <a href="./references#CD000119-bbs2-0057" title="SandercockP , CounsellC , KaneEJ . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD000024] ">Sandercock 2015</a>; <a href="./references#CD000119-bbs2-0059" title="Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid ORG 10172 (Danaparoid) and outcome after acute ischemic stroke. JAMA1998;279(16):1265‐72. ">TOAST 1998</a>). This is probably because any reductions in early recurrent ischaemic stroke or PE were offset by similar‐sized increases in intra‐ and extracranial haemorrhages (bleeding inside and outside the brain). There was no difference in the overall clinical outcome, at final follow up as measured by the proportion of people dead or dependent at the end of follow‐up (<a href="./references#CD000119-bbs2-0049" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569‐81. ">IST 1997</a>; <a href="./references#CD000119-bbs2-0057" title="SandercockP , CounsellC , KaneEJ . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD000024] ">Sandercock 2015</a>; <a href="./references#CD000119-bbs2-0059" title="Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid ORG 10172 (Danaparoid) and outcome after acute ischemic stroke. JAMA1998;279(16):1265‐72. ">TOAST 1998</a>). </p> <p>However, the Cochrane Review of the randomised trials comparing anticoagulant regimens with control in acute ischaemic stroke showed that anticoagulant therapy significantly reduced the odds of DVT by about 66%, from a rate of about 44% in those allocated to control, to 15% in those allocated to anticoagulants (<a href="./references#CD000119-bbs2-0046" title="GubitzG , SandercockP , CounsellC . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000024.pub2] ">Gubitz 2004</a>; <a href="./references#CD000119-bbs2-0057" title="SandercockP , CounsellC , KaneEJ . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD000024] ">Sandercock 2015</a>). There was also a significant 36% reduction in the odds of PE with anticoagulants. Hence, clinicians may still wish to consider the use of heparin in low dose for the prevention of DVT and life threatening PE. </p> <p>The coagulation cascades are inhibited non‐specifically at a number of different sites by standard UFH. It also inhibits platelet function (<a href="./references#CD000119-bbs2-0040" title="ChoayJ . Structure and activity of heparin and its fragments: an overview. Seminars in Thrombosis and Hemostasis1989;15(4):359‐64. ">Choay 1989</a>). These multiple blood thinning effects may increase the potential for UFH to cause haemorrhage (<a href="./references#CD000119-bbs2-0045" title="GordonDL , LinhardtR , AdamsHP . Low‐molecular‐weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clinical Neuropharmacology1990;13(6):522‐43. ">Gordon 1990</a>), and so anticoagulant agents with more specific sites of action may be associated with lower risks of haemorrhage. Two such classes of agents are LMWHs and heparinoids. LMWHs and heparinoids have a more powerful antithrombotic effect than UFH and they also have a much longer half‐life (period for which a drug actively affects the body) (<a href="./references#CD000119-bbs2-0045" title="GordonDL , LinhardtR , AdamsHP . Low‐molecular‐weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clinical Neuropharmacology1990;13(6):522‐43. ">Gordon 1990</a>; <a href="./references#CD000119-bbs2-0052" title="MeulemanDG . Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis1992;22(2):58‐65. ">Meuleman 1992</a>). Although, from the described pharmacodynamics and pharmacokinetics, LMWHs and heparinoids should be safer to use in acute stroke than UFH, a systematic review of trials of LMWH with control suggested the greater antithrombotic efficacy was offset by greater bleeding risk (<a href="./references#CD000119-bbs2-0037" title="BathP , IddendenR , BathF . Low‐molecular weight heparins and heparinoids in acute ischemic stroke. Stroke2000;31(7):1770‐8. ">Bath 2000</a>). </p> <p>Previous reviews of anticoagulants versus control provided only indirect comparisons of the safety and efficacy of the different agents and such indirect comparisons are prone to bias (<a href="./references#CD000119-bbs2-0046" title="GubitzG , SandercockP , CounsellC . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000024.pub2] ">Gubitz 2004</a>; <a href="./references#CD000119-bbs2-0055" title="SandercockPAG , van denBeltA , LindleyR , SlatteryJ . Antithrombotic therapy in acute stroke: an overview of the randomised trials. Journal of Neurology, Neurosurgery &amp; Psychiatry1993;56(1):17‐25. ">Sandercock 1993</a>). Only trials providing a direct randomised comparison of LMWHs or heparinoids with UFH will provide an unbiased assessment of the risk of haemorrhage, vascular death, and the effect on overall clinical outcome. Hence, a Cochrane Review of all the randomised trials directly comparing LMWHs or heparinoids with UFH to provide an unbiased assessment of the merits of each agent was first published in 2005 and updated in 2008. In our view, since high dose heparin is still occasionally used as a treatment for stroke (<a href="./references#CD000119-bbs2-0041" title="ChungJW , KimBJ , HanMK , KoY , LeeS , KangK , et al. Impact of guidelines on clinical practice: intravenous heparin use for acute ischemic stroke. Stroke2016;47(6):1577‐83. [DOI: 10.1161/STROKEAHA.116.012639] ">Chung 2016</a>) and low‐dose heparins are still used for prevention of DVT and PE in up to 40% of people with stroke in the USA (<a href="./references#CD000119-bbs2-0036" title="AminAN , LinJ , ThompsonS , WiederkehrD . Rate of deep‐vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurology2013;13:17. [DOI: 10.1186/1471‐2377‐13‐17] ">Amin 2013</a>), an update was required to determine whether there were any new trials that may potentially change the conclusions of the previous review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000119-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000119-sec-0035"></div> <p> <ul id="CD000119-list-0001"> <li> <p>Primary: to determine whether antithrombotic therapy with low‐molecular‐weight heparins (LMWH) or heparinoids is associated with a reduction in the proportion of people who are dead or dependent for activities in daily living compared with unfractionated heparin (UFH). </p> </li> <li> <p>Secondary: to determine whether, compared with UFH antithrombotic therapy with LMWHs or heparinoids is associated with: </p> <ul id="CD000119-list-0002"> <li> <p>a difference in deaths;</p> </li> <li> <p>a lower incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) compared with UFH; </p> </li> <li> <p>a reduction of the risk of early recurrent ischaemic strokes compared with UFH;</p> </li> <li> <p>an increased risk of fatal or disabling intracranial or extracranial haemorrhage.</p> </li> </ul> </li> </ul> </p> <p>Note: the previous versions of this Cochrane Review did not specify a primary outcome, but sought to compare the effects of LMWH and heparinoids and UFH across a range of outcomes. When this update was planned we defined the primary objective and the primary outcome to be consistent with other Cochrane Stroke Reviews, since the proportion of people who are dead or dependent for activities in daily living provides a single outcome that captures the net longer‐term effect on the person of the benefits and harms of this short‐term treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000119-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000119-sec-0036"></div> <section id="CD000119-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000119-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included all unconfounded and truly randomised trials in this Cochrane Review. In these trials, the use of low‐molecular‐weight heparins (LMWH) or heparinoids in the acute phase of ischaemic stroke was compared with standard unfractionated heparin (UFH) as control. We did not include randomised trials in which the method of allocation to treatment or control group was not adequately concealed (e.g. allocation by alternation, date of birth, hospital number, day of the week, or open random number list). This is because foreknowledge of treatment allocation might lead to biased allocation (<a href="./references#CD000119-bbs2-0053" title="Odgaard‐JensenJ , Vist GunnE , TimmerA , KunzR , AklEA , SchnemannH , et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.MR000012.pub3] ">Odgaard‐Jensen 2011</a>) and hence to misleading estimates of treatment effect. </p> </section> <section id="CD000119-sec-0039"> <h4 class="title">Types of participants</h4> <p>We excluded trials that randomised people more than 14 days after onset of the stroke and trials in people with only transient ischaemic attacks because this Cochrane Review was confined to early treatment of acute stroke. It was not essential for all people to have computed tomography (CT) scanning before entry to the trial (we were interested in people with confirmed or presumed ischaemic stroke), but we excluded trials which only included people with definite haemorrhagic stroke (stroke due to bleeding in the brain rather than blockage of an artery). </p> </section> <section id="CD000119-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Trials that compared a LMWH or heparinoid possessing anticoagulant activity with UFH were eligible. The UFH was administered either as a low dose subcutaneous regimen or a high dose intravenous one. </p> <p>The heparinoids currently available included: Org 10172/danaparoid (Orgaran), dermatan sulphate, mesoglycan, and pentosan polysulphate. The LMWHs or heparinoids were administered either intravenously or subcutaneously. We identified all trials, irrespective of whether the purpose of therapy was to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), to reduce neurological disability, or to reduce the risk of early recurrent ischaemic stroke. </p> <p>The LMWHs currently available included: Kabi 2165/dalteparin (Fragmin); CY 216/nadroparin (Fraxiparine); CY 222; PK 10169/enoxaparin (Clexane/Lovenox); LHN‐1/tinzaparin (Logiparin/Innohep); OP 2123/parnaparin (Fluxum); certoparin (Sandoparin); reviparin (Clivarine); and Sandoz LMWH. </p> </section> <section id="CD000119-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We aimed to extract from each trial the number of people originally allocated to each treatment group, and, in each treatment group, the number of people with the following outcome events. </p> <section id="CD000119-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>To be consistent with current methodological guidance from the Cochrane Stroke Group Editorial Board, we defined a primary outcome for this update of the review. In previous versions, we had defined 10 outcomes, and did not specify a single primary outcome. For this update, from the previous list of 10 outcomes, we chose 'the proportion of people who had died or needed help with daily activities at six months after randomisation' as the most clinically relevant of the 10 as the primary and we then classed the remaining nine as secondary outcomes. </p> </section> <section id="CD000119-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000119-list-0003"> <li> <p>Death from any cause during the scheduled treatment period.</p> </li> <li> <p>Death from any cause during the scheduled follow‐up period.</p> </li> <li> <p>Death from vascular causes during the scheduled treatment and follow‐up period. We defined vascular death (i.e. definitely or possibly vascular) as any death due to stroke (including complications of immobility resulting from the stroke e.g. pneumonia) or due to cardiac, haemorrhagic, embolic, or other vascular causes. </p> </li> <li> <p>Objective evidence of the occurrence of DVT detected by a systematically applied method (i.e. I125 fibrinogen scanning, doppler ultrasound or systematic X‐ray contrast venography) in all surviving participants during the scheduled treatment period (the detection of DVT after the treatment period tended to be non‐systematic and therefore potentially biased). </p> </li> <li> <p>Participants with at least one confirmed PE diagnosed during the scheduled follow‐up period, or at autopsy. </p> </li> <li> <p>Participants with any intracranial haemorrhage or haemorrhagic transformation of the cerebral infarct confirmed by systematic CT or magnetic resonance (MR) scanning at the end of the treatment period, or by autopsy. </p> </li> <li> <p>Participants with symptomatic intracranial haemorrhage or haemorrhagic transformation of the cerebral infarct (dead brain tissue) confirmed by CT or MR scanning after clinical deterioration, or by autopsy. </p> </li> <li> <p>Participants with any major or minor extracranial haemorrhage. The definition of major haemorrhage was usually taken from the original article but if none was given we defined it as any bleed resulting in death, transfusion or operation. </p> </li> <li> <p>Participants with a recurrent stroke during the scheduled treatment period that was either definitely ischaemic (haemorrhage excluded on CT or MR scan or at autopsy) or in which the pathology was unknown because no CT or MR or autopsy was performed. </p> </li> </ul> </p> </section> </section> </section> <section id="CD000119-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. We attempted to identify all relevant trials regardless of language or publication status, and arranged translation of relevant papers where necessary. </p> <section id="CD000119-sec-0045"> <h4 class="title">Electronic searches</h4> <p>With the assistance of the Managing Editor, we searched the Cochrane Stroke Group Trials Register (date last searched 6 February 2017). In addition, we searched the following bibliographic databases and trial registers. </p> <p> <ul id="CD000119-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 1) in the Cochrane Library (searched February 2017, <a href="./appendices#CD000119-sec-0101">Appendix 1</a>); </p> </li> <li> <p>MEDLINE in Ovid (searched February 2017, <a href="./appendices#CD000119-sec-0102">Appendix 2</a>); </p> </li> <li> <p>Embase in Ovid (searched February 2017, <a href="./appendices#CD000119-sec-0103">Appendix 3</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>, searched February 2017, <a href="./appendices#CD000119-sec-0104">Appendix 4</a>); </p> </li> <li> <p>EU Clinical Trials Register (<a href="http://clinicaltrialsregister.eu/ctr-search/search" target="_blank">clinicaltrialsregister.eu/ctr‐search/search</a>, search February 2017, <a href="./appendices#CD000119-sec-0104">Appendix 4</a>); </p> </li> <li> <p>Stroke Trials Registry (<a href="http://strokecenter.org/trials/" target="_blank">strokecenter.org/trials/</a>, searched February 2017, <a href="./appendices#CD000119-sec-0104">Appendix 4</a>); </p> </li> <li> <p>ISRCTN Registry (<a href="http://isrctn.com/" target="_blank">isrctn.com/</a>; searched February 2017, <a href="./appendices#CD000119-sec-0104">Appendix 4</a>) (previously Current Controlled Trials (www.controlled‐trials.com, searched September 2015); and </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (<a href="http://who.int/ictrp/en/" target="_blank">who.int/ictrp/en/</a>, searched February 2017, <a href="./appendices#CD000119-sec-0104">Appendix 4</a>). </p> </li> </ul> </p> </section> <section id="CD000119-sec-0046"> <h4 class="title">Searching other resources</h4> <p>In an effort to identify further published, unpublished and ongoing trials, we screened the reference lists of all relevant trials. </p> <p>For previous versions of this review, we had:</p> <p> <ul id="CD000119-list-0005"> <li> <p>contacted the following companies that market LMWHs or heparinoids: Alfa Wasserman (parnaparin and dermatan sulphate), Kabi (dalteparin), Knoll (reviparin), Leo (tinzaparin), Mediolanum (dermatan sulphate), Novo (tinzaparin), Organon (danaparoid), Rhone‐Poulenc Rorer (enoxaparin), Sandoz (Sandoz LMWH), and Sanofi Winthrop (nadroparin and CY222); and </p> </li> <li> <p>consulted a comprehensive guide to pharmaceutical development in the stroke field (MEDSTRATEGY 1995). </p> </li> </ul> </p> </section> </section> <section id="CD000119-sec-0047"> <h3 class="title" id="CD000119-sec-0047">Data collection and analysis</h3> <p>Two review authors (PS and TL), with the assistance of the Cochrane Stroke Group Information Specialist, performed the searches for this update. The same two review authors independently screened abstracts and titles, and excluded irrelevant studies. We retrieved and independently assessed the full articles of the remaining studies based on the inclusion and exclusion criteria. We resolved disagreements by discussion. </p> <section id="CD000119-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (PS and CC for the original review; PS and SS for second update; PS and TL for this update) independently selected trials to be included in the review. We resolved disagreements by discussion. Two review authors also assessed the methodological quality of each trial separately. </p> </section> <section id="CD000119-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>The two review authors (PS and TL) independently extracted and cross‐checked the data. We extracted data such as the number of people with each outcome event, by allocated treatment group, irrespective of compliance, and whether or not the person was subsequently deemed ineligible or otherwise excluded from treatment or follow‐up. This approach was applied to allow for an intention‐to‐treat (ITT) analysis. We sought data on whether or not CT or MR scanning was performed prior to randomisation. If any of the above data items were not available in the publications, we sought further information by correspondence with the trial authors. We checked to see whether there was evidence to suggest that previously excluded studies should be included and whether ongoing or studies awaiting assessment could be included, but further information was not available for any of these studies. </p> </section> <section id="CD000119-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For previous versions of this review, the authors did not use a scoring system to assess quality but only assessed risk of bias of included studies. In the previous version, the table of included studies gave details of the randomisation method, blinding, whether an ITT analysis was possible from the published data, and the number of people lost to follow‐up. The only dimension of risk of bias that we graded was allocation concealment. However, for this update, we scored the key elements of risk of bias for each included study according to current Cochrane guidelines (<a href="./references#CD000119-bbs2-0047" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) and generated a risk of bias summary table. </p> </section> <section id="CD000119-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>Trials of each type of anticoagulant, (LMWHs or heparinoids) were compared to UFH to assess whether there was any difference between these classes of anticoagulants. We reported relative effects as odds ratios (OR, the ratio of the odds of an unfavourable outcome among people treated with either LMWHs or heparinoids versus UFH). We calculated the OR using the Peto fixed‐effect method with its 95% confidence interval (CI). </p> </section> <section id="CD000119-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>All the studies included in this review were trials in which all the participants were randomised and followed up for a fixed and pre‐defined period. All analyses were by ITT where possible. </p> </section> <section id="CD000119-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted original investigators to ask for missing data whenever possible. When this was not possible, we calculated best‐ and worst‐case scenarios: the best‐case scenario would mean participants with missing data were alive and the worst‐case scenario would mean participants with missing data were dead. </p> </section> <section id="CD000119-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity between study results with the I² statistic which measures the percentage of the variability in effect estimates attributable to heterogeneity (rather than sampling error). We considered a value greater than 50% as substantial heterogeneity. </p> </section> <section id="CD000119-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We produced funnel plots for two outcomes, death from all causes during treatment period and death from all causes during follow‐up period, to assess the presence of publication bias. </p> </section> <section id="CD000119-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 for analysis (<a href="./references#CD000119-bbs2-0054" title="Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Trials of each type of anticoagulant, namely LMWHs or heparinoids were compared to UFH to assess whether there was any difference between these classes of anticoagulants. We also assessed the effects of different doses of LMWHs or heparinoids against UFH (5000 IU 12‐hourly), applying a test for trend, with due allowance for the fact that such indirect comparisons are prone to bias. </p> </section> <section id="CD000119-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analysis of the type of anticoagulant agent used (either LMWHs or heparinoids versus UFH) and the dose of anticoagulant used. </p> </section> <section id="CD000119-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to determine how sensitive results are to reasonable changes in the assumptions that are made. Furthermore, the potential impact of missing data on the findings of the review was addressed in the <a href="./full#CD000119-sec-0059">Results</a> section (risk of bias, attrition bias). We did not perform a sensitivity analysis based on the frequency of CT or MR scanning at baseline as all studies scanned 100% of patients before entry. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000119-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000119-sec-0059"></div> <section id="CD000119-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD000119-sec-0061"> <h4 class="title">Results of the search</h4> <p>See the PRISMA flow diagram (<a href="#CD000119-fig-0001">Figure 1</a>). After the removal of redundant records and previously included trials, we screened a total of 2620 records of titles and abstracts. We selected 17 apparently new trials and, of these, we obtained the full text reports for 10. We then excluded all of these studies after review, leaving no new trials for inclusion. Hence, from the last update, the number of included studies remained the same at nine trials. However, there was a sub‐analysis of the <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> trial which was published in 2009 that contained some additional relevant outcome data that was subsequently included in this updated review. </p> <div class="figure" id="CD000119-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD000119-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD000119-sec-0062"> <h4 class="title">Included studies</h4> <p>We included nine trials with a total number of 3137 participants (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Dumas-1994" target="_blank">Dumas 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hageluken-1992" target="_blank">Hageluken 1992</a>; <a href="./references#CD000119-bbs2-0003" title="HillbomM , ErilaT , FlosbachC , SotaniemiK , TatlisumakT , SarnaS , et al. Enoxaparin, a low‐molecular‐weight heparin (LWMH) may be superior to standard heparin in the prevention of deep‐vein thrombosis (DVT) in stroke patients. European Journal of Neurology1998;5(Suppl 3):S110. HillbomM , ErilaT , FlosbachCW , SotaniemiK , SarnaS , KasteM . Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherosclerotic stroke. Proceedings of the 17th Congress of the International Society on Thrombosis and Haemostasis; 1999 August 14‐21; Washington, DC, USA. 1999. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Comparison of the efficacy and safety of the low‐molecular‐weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischaemic stroke. Blood1999;94(Suppl 1):183a. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind study. Acta Neurologica Scandinavica2002;106(2):84‐92. ">Hillbom 1998</a>; <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-PROTECT-2006" target="_blank">PROTECT 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Stiekema-1988" target="_blank">Stiekema 1988</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-TRACE-2004" target="_blank">TRACE 2004</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Turpie-1992" target="_blank">Turpie 1992</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Wong-2000" target="_blank">Wong 2000</a>). Three of the trials have not yet been published in full (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hageluken-1992" target="_blank">Hageluken 1992</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Stiekema-1988" target="_blank">Stiekema 1988</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Wong-2000" target="_blank">Wong 2000</a>). The <a href="./references#CD000119-sec-0119" title="">Characteristics of included studies</a> table provides details of the included trials. </p> <p>Most participants were enrolled within 72 hours of the stroke, except in two studies which recruited participants less than 24 hours after stroke onset (<a href="./references#CD000119-bbs2-0005" title="DienerH‐C , RingelsteinEB , vonKummerR , LandgrafH , KoppenhagenK , HarenbergJ , et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low‐molecular‐weight heparin certoparin. Results of the PROTECT Trial. Stroke2006;37(1):139‐44. ">PROTECT 2006</a>; <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a>). The age of participants in the included trials ranged from 21 years to 91 years with a mean of 68 years. Most trials recruited slightly more males than females. Four trials compared danaparoid (a heparinoid) with unfractionated heparin (UFH) (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Dumas-1994" target="_blank">Dumas 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hageluken-1992" target="_blank">Hageluken 1992</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Stiekema-1988" target="_blank">Stiekema 1988</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Turpie-1992" target="_blank">Turpie 1992</a>) and five compared low‐molecular‐weight heparin (LMWH) with UFH (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hillbom-1998" target="_blank">Hillbom 1998</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-PREVAIL-2007" target="_blank">PREVAIL 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-PROTECT-2006" target="_blank">PROTECT 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-TRACE-2004" target="_blank">TRACE 2004</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Wong-2000" target="_blank">Wong 2000</a>). All trials administered treatment by the subcutaneous route, although in one trial, treatment began with a single intravenous loading dose of danaparoid (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Stiekema-1988" target="_blank">Stiekema 1988</a>). </p> <p>All the trials reported deaths, either during the treatment or follow‐up periods. The scheduled period of treatment ranged from 6 days to 16 days. Duration of follow‐up for all the trials was three months except for two trials, which followed up for 14 days (<a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>) and 28 days (<a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a>). All the trials routinely performed computed tomography (CT) scanning in all participants before randomisation to exclude primary intracerebral haemorrhage as a cause of the stroke. </p> <p>Attempts to contact the authors of a completed trial to gain additional information have been unsuccessful, so we were only able to include the outcome data on CT‐confirmed haemorrhage from <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a>. </p> </section> <section id="CD000119-sec-0063"> <h4 class="title">Excluded studies</h4> <p>We excluded 16 studies in this updated review. We had excluded eight trials from the previous review. In total, we excluded 24 studies for a variety of reasons. The <a href="./references#CD000119-sec-0120" title="">Characteristics of excluded studies</a> table provides summary details. </p> <p>We excluded one study, comparing enoxaparin with UFH in 38 participants with stroke, because we had sought outcome data on the stroke subset of participants but these data were not provided (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-EMSG-1996" target="_blank">EMSG 1996</a>). We excluded another two studies, comparing enoxaparin with UFH, because the stroke participants were not analysed separately and we were concerned that the participants in these two reports overlapped (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Harenberg-1999" target="_blank">Harenberg 1999</a>; <a href="./references#CD000119-bbs2-0019" title="HarenbergJ , KallenbachB , MartinU , DempfleCE , ZimmermannR , KublerW , et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep‐vein thrombosis in medical patients. Thrombosis Research1990;59(3):639‐50. HarenbergJ , RoebruckP , StehleG , HabscheidW , BiegholdtM , HeeneDL , et al. Heparin study in internal medicine (HESIM): design and preliminary results. Thrombosis Research1992;68(1):33‐43. ">HESIM 1990</a>). We also excluded studies where the target participants were not acute ischaemic stroke (<a href="./references#CD000119-bbs2-0010" title="AssadianA , KnoblP , HublW , SenekowitschC , KlinglerA , PfaffelmeyerN , et al. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. Journal of Vascular Surgery2008;47(3):537‐42. ">Assadian 2008</a>; <a href="./references#CD000119-bbs2-0025" title="NCT01763606 . Enoxaparin versus aspirin in patients with cancer and stroke. clinicaltrials.gov/ct2/show/NCT01763606 (first received 20 December 2012). ">NCT01763606</a>; <a href="./references#CD000119-bbs2-0014" title="HullRD , SchellongSM , TapsonVF , MonrealM , SamamaMM , NicolP , et al. Extended‐duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Annals of Internal Medicine2010;153(1):8‐18. [DOI: 10.7326/0003‐4819‐153‐1‐201007060‐00004] ">EXCLAIM 2010</a>; <a href="./references#CD000119-bbs2-0027" title="Nikc EvicLD , SavicMB , PlavsicAT , HrkovicMK . Applying of LMWH (clexane) and results of early rehabilitation in patients after ischemic stroke. International Journal of Stroke2006;1(Suppl 1):153. ">Nikc Evic 2006</a>). </p> <p>We excluded a large number of studies because the intervention did not include unfractionated heparin (<a href="./references#CD000119-bbs2-0011" title="DunatovS , AntoncicI , Strenja‐LinicI , Tuskan‐MoharL . Low molecular weight heparin (LMWH) as an adjunct to thrombolysis for acute stroke. International Journal of Stroke2008;3 (Suppl 1):238. ">Dunatov 2008</a>; <a href="./references#CD000119-bbs2-0013" title="EgbertsJFM , SommerW . Multicentre, randomised, assessor‐blind, dose‐comparative study of Org 10172 (Orgaran) in the treatment of acute ischaemic stroke. Personal communication by letter1996. ">EUROTOAST 1996</a>; <a href="./references#CD000119-bbs2-0016" title="GengS , WangY , LiuP . Intravenous drip of urokinase combined with low molecular weight heparin in the treatment of acute cerebral infarction. Practical Journal of Medicine and Pharmacy2004;21(7):604‐6. ">Geng 2004</a>; <a href="./references#CD000119-bbs2-0021" title="CohenAT , SpiroTE , BüllerHR , HaskellL , HuD , HullR , MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine2013;368(6):513‐52. [DOI: 10.1056/NEJMoa1111096] ">MAGELLAN 2013</a>; <a href="./references#CD000119-bbs2-0023" title="MikulikR , DufekM , GoldemundD , ReifM . A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke. European Journal of Neurology2006;13(10):1106‐11. ">Mikulik 2006</a>; <a href="./references#CD000119-bbs2-0026" title="Necioglu OrkenD , KenangilG , OzkurtH , GunerC , GundogduL , BasakM , et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. The Neurologist2009;15(6):329‐31. ">Necioglu Orken 2009</a>; <a href="./references#CD000119-bbs2-0030" title="TrencevR , StojanovM , Petrovska‐CvetkovskaD , GeorgievskaA , BanevaN , Radulovic‐BekarovskaS . Low‐molecular‐weight heparin vs aspirin in treatment of cardioembolic stroke. International Journal of Stroke2008; Vol. 3, issue Suppl 1:315‐6. ">Trencev 2008</a>; <a href="./references#CD000119-bbs2-0033" title="XingZW , ShiYD . Clinical observation of combined clopidogrel and low molecular heparin in progressive ischemic stroke. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(1):44‐6. ">Xing 2006</a>) or LMWH (<a href="./references#CD000119-bbs2-0031" title="TrouillasP , DerexL , PhilippeauF , CakmakS , NighoghossianN , ZengL . RT‐PA and heparin in the LYON RT‐PA protocol: beneficial effect of intravenous heparin on outcome and intracerebral bleeding at specific times of initiation. Cerebravascular Diseases2008;25(Suppl 2):42‐3. ">Trouillas 2008</a>). One study was confounded because aspirin was part of its comparator (<a href="./references#CD000119-bbs2-0020" title="IRCT201109067495N1 . Clinical trial on enoxaparine and aspirin effects on mobility problems of non‐hemorrhagic stroke patients. en.search.irct.ir/view/7105 (first received 10 December 2011). ">IRCT201109067495N1</a>), and we excluded another study because the two treatment arms were confounded by the co‐administration of different warfarin regimens (<a href="./references#CD000119-bbs2-0015" title="FeizF , SedghiR , SalehiA , HatamN , BahmeiJ , Borhani‐HaghigiA . Study of the efficacy, safety and tolerability of low‐molecular weight heparin vs unfractionated heparin as bridging therapy for patients with embolic stroke due to atrial fibrillation. Journal of Vascular and Interventional Neurology2016;9(1):35‐41. ">Feiz 2016</a>). We excluded one trial because the treatment arms were confounded by differing background treatments (<a href="./references#CD000119-bbs2-0018" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , Turcanova‐KoprusakovaM , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke – pilot study. Biomedical Papers2016;160(4):543‐8. NCT01862978 . Safety and efficacy of heparin and nadroparin in the acute phase of ischaemic stroke (Heparinas). clinicaltrials.gov/ct2/show/NCT01862978 (first received 20 May 2013). ">Heparinas 2013</a>). One trial (<a href="./references#CD000119-bbs2-0028" title="SzirmaiI , FendlerK , KollárL , RomhányiM . Clinical experience with heparinoid sodium pentosan polysulphate (SP54) in treatment of cerebral ischaemia. Folia Haematologia (Leipzig)1986;113(1‐2):278‐88. ">Szirmai 1986</a>) proved on review to have no control group, and we excluded another trial because no data were included in the report (<a href="./references#CD000119-bbs2-0022" title="McCarthyS , McWalterR , DurkinCJ , HallawiAH . Org 10172 for the prophylaxis of deep venous thrombosis in the legs. A protocol to establish the efficacy and safety of once or twice daily subcutaneous Org 10172 injections vs placebo in 3 groups of 60 non‐haemorrhagic stroke victims. Unpublished protocol. ">McCarthy 1993</a>). </p> <p>Two trials published in China were only available as abstracts (<a href="./references#CD000119-bbs2-0029" title="TanA . The application research on the treatment of acute ischemic stroke by using low molecular weight heparins and small dose of heparins. Journal of Medical Theory and Practice2002;15(11):1246‐7. ">Tan 2002</a>; <a href="./references#CD000119-bbs2-0032" title="WangZY , WangLC , ChenC , GenJY , GaoYS . A controlled study on the treatment of acute progressive cerebral infarction by continuous anticoagulation with small doses of heparin. Chinese Critical Care Medicine2012;24(5):290‐3. ">Wang 2012</a>). We attempted to contact relevant authors as well as seek help from colleagues from China to obtain the full text articles but to no avail. A trial of CY 216 compared with UFH was stopped prematurely but remains unpublished and unavailable despite multiple contacts with the author (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Moulin-1994" target="_blank">Moulin 1994</a>). There are two apparently ongoing trials, but we have been unable to contact the authors to gain further information: one of enoxaparin versus UFH (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Aventis-2002" target="_blank">Aventis 2002</a>), and one of LMWH plus warfarin versus UFH plus warfarin (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Young-2001" target="_blank">Young 2001</a>). </p> <p>While there are a large number of excluded studies, they all had small sample sizes, most were confounded in various ways and the inclusion of these studies would not be likely to reduce the random error or degree of bias in the estimates we have derived. </p> </section> </section> <section id="CD000119-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to <a href="#CD000119-fig-0002">Figure 2</a> and <a href="#CD000119-fig-0003">Figure 3</a> for graphical representation of the risk of bias across all the nine studies. None of the included studies was assessed at low risk of bias in all categories, as each had some threats to validity. We considered some of the studies to have an unclear risk of bias due to the lack of details provided from the paper published. Overall, we judged there to be a moderate risk of bias, chiefly because of inadequate information about allocation concealment and risk of attrition bias. </p> <div class="figure" id="CD000119-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000119-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD000119-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000119-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD000119-sec-0065"> <h4 class="title">Allocation</h4> <p>The method of randomisation was described and considered adequate with low risk of bias in three out of nine of the included trials: <a href="./references#CD000119-bbs2-0003" title="HillbomM , ErilaT , FlosbachC , SotaniemiK , TatlisumakT , SarnaS , et al. Enoxaparin, a low‐molecular‐weight heparin (LWMH) may be superior to standard heparin in the prevention of deep‐vein thrombosis (DVT) in stroke patients. European Journal of Neurology1998;5(Suppl 3):S110. HillbomM , ErilaT , FlosbachCW , SotaniemiK , SarnaS , KasteM . Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherosclerotic stroke. Proceedings of the 17th Congress of the International Society on Thrombosis and Haemostasis; 1999 August 14‐21; Washington, DC, USA. 1999. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Comparison of the efficacy and safety of the low‐molecular‐weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischaemic stroke. Blood1999;94(Suppl 1):183a. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind study. Acta Neurologica Scandinavica2002;106(2):84‐92. ">Hillbom 1998</a> used a computer program (ACR/BIOM/STAT) to generate the randomisation sequence and a computer‐generated randomisation list was used in <a href="./references#CD000119-bbs2-0005" title="DienerH‐C , RingelsteinEB , vonKummerR , LandgrafH , KoppenhagenK , HarenbergJ , et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low‐molecular‐weight heparin certoparin. Results of the PROTECT Trial. Stroke2006;37(1):139‐44. ">PROTECT 2006</a>. <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a>, <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>, <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a>, <a href="./references#CD000119-bbs2-0008" title="MagnaniHN , EgbertsJFM . A preliminary report of a multi‐centre, assessor‐blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004‐010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands1992. TurpieAGG . Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis1992;22(2):92‐8. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1991;65:753. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A low‐molecular‐weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine1992;117(5):353‐7. ">Turpie 1992</a> and <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a> reported that the trial was randomised. <a href="./references#CD000119-bbs2-0001" title="DumasR , WoitinasF , KutnowskiM , NikolicI , BerberichR , AbedinpourF , et al. A multi‐centre double blind randomized study to compare the safety and efficacy of once‐daily ORG 10172 and twice‐daily low‐dose heparin in preventing deep‐vein thrombosis in patients with acute ischaemic stroke. Age and Ageing1994;23(6):512‐6. HagelukenC , EgbertsJ , StiekemaJ . A multi‐centre, assessor‐blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non‐haemorrhagic stroke of recent onset (protocol 87038). Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands1992. ">Dumas 1994</a> used the sealed envelope method for randomisation. None of these six trials provided details on the method of random sequence generation. </p> <p>Allocation concealment was adequate in <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>, which used a central randomisation system. Allocation concealment was unclear for six trials: in <a href="./references#CD000119-bbs2-0005" title="DienerH‐C , RingelsteinEB , vonKummerR , LandgrafH , KoppenhagenK , HarenbergJ , et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low‐molecular‐weight heparin certoparin. Results of the PROTECT Trial. Stroke2006;37(1):139‐44. ">PROTECT 2006</a> the report stated only that "treatment allocation was kept strictly confidential and was available only to authorised persons", and in the other five, no details were given (<a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a>; <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>; <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a>; <a href="./references#CD000119-bbs2-0008" title="MagnaniHN , EgbertsJFM . A preliminary report of a multi‐centre, assessor‐blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004‐010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands1992. TurpieAGG . Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis1992;22(2):92‐8. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1991;65:753. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A low‐molecular‐weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine1992;117(5):353‐7. ">Turpie 1992</a>; <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a>). In <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hageluken-1992" target="_blank">Hageluken 1992</a> where there was a 3:1 treatment allocation to danaparoid and UFH respectively, there was a relative shortfall in the number of participants allocated to control with 118 allocated to danaparoid UFH and only 27 to control (and not about 40 as would be expected if randomisation had achieved a 3:1 ratio), which may have occurred by chance. However, there may be other explanations (such as deliberate or inadvertent subversion of the randomisation process, or unequal proportions of participants excluded after randomisation). Therefore, we performed analyses with this trial included and excluded, to assess its influence on the overall estimates of effect on the different outcomes. </p> </section> <section id="CD000119-sec-0066"> <h4 class="title">Blinding</h4> <p>To reduce bias in detecting deep vein thrombosis (DVT), pulmonary embolism (PE), symptomatic intracranial haemorrhage and minor extracranial haemorrhages, adequate blinding is important. Four trials were double‐blinded, where treatment allocation was not revealed to outcome assessors, participants and physicians (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Dumas-1994" target="_blank">Dumas 1994</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hillbom-1998" target="_blank">Hillbom 1998</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-PROTECT-2006" target="_blank">PROTECT 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Turpie-1992" target="_blank">Turpie 1992</a>). <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a>, <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>, and <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a> reported their assessors were single blinded. <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> and <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a> did not use any form of blinding and were assessed at high risk of performance and detection bias. </p> </section> <section id="CD000119-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD000119-bbs2-0003" title="HillbomM , ErilaT , FlosbachC , SotaniemiK , TatlisumakT , SarnaS , et al. Enoxaparin, a low‐molecular‐weight heparin (LWMH) may be superior to standard heparin in the prevention of deep‐vein thrombosis (DVT) in stroke patients. European Journal of Neurology1998;5(Suppl 3):S110. HillbomM , ErilaT , FlosbachCW , SotaniemiK , SarnaS , KasteM . Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherosclerotic stroke. Proceedings of the 17th Congress of the International Society on Thrombosis and Haemostasis; 1999 August 14‐21; Washington, DC, USA. 1999. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Comparison of the efficacy and safety of the low‐molecular‐weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischaemic stroke. Blood1999;94(Suppl 1):183a. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind study. Acta Neurologica Scandinavica2002;106(2):84‐92. ">Hillbom 1998</a> and <a href="./references#CD000119-bbs2-0008" title="MagnaniHN , EgbertsJFM . A preliminary report of a multi‐centre, assessor‐blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004‐010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands1992. TurpieAGG . Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis1992;22(2):92‐8. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1991;65:753. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A low‐molecular‐weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine1992;117(5):353‐7. ">Turpie 1992</a> stated explicitly that there were no losses to follow‐up. <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-PREVAIL-2007" target="_blank">PREVAIL 2007</a> and <a href="./references#CD000119-bbs2-0005" title="DienerH‐C , RingelsteinEB , vonKummerR , LandgrafH , KoppenhagenK , HarenbergJ , et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low‐molecular‐weight heparin certoparin. Results of the PROTECT Trial. Stroke2006;37(1):139‐44. ">PROTECT 2006</a> published trial flow charts, which detailed the degree of losses to follow‐up that was sufficient to be a significant source of attrition bias in both trials. The numbers of participants lost to follow‐up was not stated in five trials (<a href="./references#CD000119-bbs2-0001" title="DumasR , WoitinasF , KutnowskiM , NikolicI , BerberichR , AbedinpourF , et al. A multi‐centre double blind randomized study to compare the safety and efficacy of once‐daily ORG 10172 and twice‐daily low‐dose heparin in preventing deep‐vein thrombosis in patients with acute ischaemic stroke. Age and Ageing1994;23(6):512‐6. HagelukenC , EgbertsJ , StiekemaJ . A multi‐centre, assessor‐blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non‐haemorrhagic stroke of recent onset (protocol 87038). Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands1992. ">Dumas 1994</a>; <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a>; <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>; <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a>; <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a>). </p> </section> <section id="CD000119-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Clinical trial registration details or study protocols were available for only one study (<a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>). The primary publication for <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> did not include numbers of participants who were dead or dependent at follow‐up (a secondary paper in 2009 reported mean modified Rankin Scale: <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>). Data on recurrent strokes during the treatment period (up to 14 days) were reported in a subanalysis of <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> published in 2009. Since these were secondary outcomes for the trial, we considered <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> at low risk of reporting bias. </p> <p>For the remainder of the included studies, it was unclear whether any of the older studies were free from reporting bias, largely because study protocols were not available. It is of note that only two provided information on functional outcomes: one on neurological deterioration within 10 days (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Wong-2000" target="_blank">Wong 2000</a>); and the other on the Barthel index, a measure of functional independence (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-TRACE-2004" target="_blank">TRACE 2004</a>). Neither <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> nor <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a> provided numerical data. Given the overall quality of the older study reports, and their lack of detail on exactly what data were collected, one cannot rule out a degree of selective reporting of outcomes (in that era, internationally agreed reporting standards for clinical trials had not been published). </p> </section> <section id="CD000119-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>We sought evidence of publication bias but the number of studies was small (hence limiting the value of this analysis), and the funnel plots did not provide strong evidence of publication bias (<a href="#CD000119-fig-0004">Figure 4</a>; <a href="#CD000119-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD000119-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during treatment period" data-id="CD000119-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during treatment period </p> </div> </div> </div> <div class="figure" id="CD000119-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during follow‐up" data-id="CD000119-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during follow‐up </p> </div> </div> </div> </section> </section> <section id="CD000119-sec-0070"> <h3 class="title" id="CD000119-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD000119-tbl-0001"><b>Summary of findings for the main comparison</b> Low‐molecular‐weight heparins or heparinoids compared with unfractionated heparin for acute ischaemic stroke</a> </p> <section id="CD000119-sec-0071"> <h4 class="title">Outcome analysis 1.1: Dead or dependent at the end of follow‐up</h4> <p>None of the trials reported this outcome in a form that enabled us to include them for this analysis. </p> </section> <section id="CD000119-sec-0072"> <h4 class="title">Outcome analysis 1.2: Death from all causes during treatment period</h4> <p>During the anticoagulation period with LMWH, heparinoids, or UFH, an increased risk of death due to intracranial haemorrhage would only be apparent if most participants had autopsies or CT brain scan shortly before death. However, this was generally not the case, so reliable attribution of any deaths during the treatment period to intracranial haemorrhages was not possible. Intracranial haemorrhage carries an early case fatality of 50% or more, so analysis of deaths from all causes during the treatment period would be more sensitive to an excess of deaths related to intracranial haemorrhage than an analysis of all deaths during the whole of follow‐up. Death data were available from eight trials (<a href="./references#CD000119-bbs2-0001" title="DumasR , WoitinasF , KutnowskiM , NikolicI , BerberichR , AbedinpourF , et al. A multi‐centre double blind randomized study to compare the safety and efficacy of once‐daily ORG 10172 and twice‐daily low‐dose heparin in preventing deep‐vein thrombosis in patients with acute ischaemic stroke. Age and Ageing1994;23(6):512‐6. HagelukenC , EgbertsJ , StiekemaJ . A multi‐centre, assessor‐blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non‐haemorrhagic stroke of recent onset (protocol 87038). Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands1992. ">Dumas 1994</a>; <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a>; <a href="./references#CD000119-bbs2-0003" title="HillbomM , ErilaT , FlosbachC , SotaniemiK , TatlisumakT , SarnaS , et al. Enoxaparin, a low‐molecular‐weight heparin (LWMH) may be superior to standard heparin in the prevention of deep‐vein thrombosis (DVT) in stroke patients. European Journal of Neurology1998;5(Suppl 3):S110. HillbomM , ErilaT , FlosbachCW , SotaniemiK , SarnaS , KasteM . Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherosclerotic stroke. Proceedings of the 17th Congress of the International Society on Thrombosis and Haemostasis; 1999 August 14‐21; Washington, DC, USA. 1999. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Comparison of the efficacy and safety of the low‐molecular‐weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischaemic stroke. Blood1999;94(Suppl 1):183a. HillbomM , ErilaT , SotaniemiK , TatlisumakT , SarnaS , KasteM . Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind study. Acta Neurologica Scandinavica2002;106(2):84‐92. ">Hillbom 1998</a>; <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>; <a href="./references#CD000119-bbs2-0005" title="DienerH‐C , RingelsteinEB , vonKummerR , LandgrafH , KoppenhagenK , HarenbergJ , et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low‐molecular‐weight heparin certoparin. Results of the PROTECT Trial. Stroke2006;37(1):139‐44. ">PROTECT 2006</a>; <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>; <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a>; <a href="./references#CD000119-bbs2-0008" title="MagnaniHN , EgbertsJFM . A preliminary report of a multi‐centre, assessor‐blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004‐010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands1992. TurpieAGG . Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis1992;22(2):92‐8. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1991;65:753. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A low‐molecular‐weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine1992;117(5):353‐7. ">Turpie 1992</a>) with 3102 participants (98.8% of the total participants included in the review). Overall, there was no significant difference in all cause death during the scheduled treatment period between LMWH or heparinoids and UFH (OR 1.06, 95% CI 0.78 to 1.46, low quality evidence; <a href="./references#CD000119-fig-0006" title="">Analysis 1.2</a>). There was no significant heterogeneity (I² = 0 %). </p> </section> <section id="CD000119-sec-0073"> <h4 class="title">Outcome analysis 1.3: Death from all causes during follow‐up</h4> <p>Data from eight trials with 3102 participants were available for this outcome. There was no significant difference between LMWH or heparinoid and UFH (OR 0.98, 95% CI 0.79 to 1.23, low quality evidence; <a href="./references#CD000119-fig-0007" title="">Analysis 1.3</a>). There was no significant heterogeneity (I² = 0 %) among the interventions. The confidence interval was compatible with substantial harm (an extra 2 deaths per 100 people treated) and substantial benefit (2 fewer deaths per 100 people treated). Any ‐ even a small ‐ excess of deaths associated with danaparoid or LMWH could clearly offset any benefits from reductions in DVT and PE. </p> </section> <section id="CD000119-sec-0074"> <h4 class="title">Outcome analysis 1.4: Vascular death during follow‐up</h4> <p>Significant and important beneficial or adverse effects on specific causes of death may be missed if crude analysis was undertaken only on deaths from all causes. Important effects of treatment on vascular deaths may be obscured if a large proportion of deaths were due to non‐vascular causes (and hence very unlikely to be influenced by anticoagulant agents). Data on cause‐specific mortality in each treatment group with 1038 participants (33% of the total participants in the review) were available for this outcome. There was no significant difference in vascular death between those allocated danaparoid or LMWH versus those allocated UFH (OR 1.15, 95% CI 0.72 to 1.85, I² = 0%, low quality evidence; <a href="./references#CD000119-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD000119-sec-0075"> <h4 class="title">Outcome analysis 1.5: DVT during treatment period</h4> <p>Seven trials that included a total of 2585 participants (82.4% of the total number of participants included in the review) reported data on DVT detected systematically. Methods of detecting DVT were variable. Four trials used I¹²⁵ fibrinogen scanning, two mostly used contrast venography, and one used Doppler ultrasound detecting only proximal leg DVT. Nevertheless, some participants either did not have the appropriate investigation or had an inadequate assessment of DVT. For instance, in <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hillbom-1998" target="_blank">Hillbom 1998</a> 30 participants allocated enoxaparin and 34 allocated UFH did not have venography or had an inadequate examination; in <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Dumas-1994" target="_blank">Dumas 1994</a> four participants allocated UFH did not have valid I¹²⁵ fibrinogen scans or venograms; in <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hageluken-1992" target="_blank">Hageluken 1992</a> 16 participants allocated to danaparoid and eight participants allocated to UFH did not have valid DVT assessments; and in <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-PREVAIL-2007" target="_blank">PREVAIL 2007</a> 218 participants allocated enoxaparin and 209 allocated UFH had no or an inadequate assessment of DVT. These participants were retained in their original treatment groups for the main analysis, and we assumed that none had a DVT, except for <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>, where there were many excluded participants and so DVT was analysed in the per‐protocol efficacy population. </p> <p>The proportion of participants not undergoing venography was quite high in a number of studies. A modified worst‐case scenario analysis was performed with the assumption that the excluded participants in the LMWH or heparinoid arm had a DVT rate that was equal to the highest rate in any arm in any included trial (31% in the <a href="./references#CD000119-bbs2-0008" title="MagnaniHN , EgbertsJFM . A preliminary report of a multi‐centre, assessor‐blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004‐010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands1992. TurpieAGG . Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis1992;22(2):92‐8. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1991;65:753. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A low‐molecular‐weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine1992;117(5):353‐7. ">Turpie 1992</a> UFH arm) and those excluded in the UFH arm had a DVT rate equal to the lowest rate in any arm (7% in the <a href="./references#CD000119-bbs2-0005" title="DienerH‐C , RingelsteinEB , vonKummerR , LandgrafH , KoppenhagenK , HarenbergJ , et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low‐molecular‐weight heparin certoparin. Results of the PROTECT Trial. Stroke2006;37(1):139‐44. ">PROTECT 2006</a> LMWH arm). This method has been applied in other Cochrane Reviews (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#REF-Macleod-2005" target="_blank">Macleod 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#REF-Sandercock-2003a" target="_blank">Sandercock 2003a</a>). </p> <p>As a whole, allocation to LMWH or heparinoid was associated with a significant reduction in DVT (OR 0.55, 95% CI 0.44 to 0.70, P &lt; 0.00001, I² = 0%, low quality evidence; <a href="./references#CD000119-fig-0009" title="">Analysis 1.5</a>). However, the result was no longer statistically significant in the modified worst‐case scenario analysis (OR 0.86, 95% CI 0.70 to 1.06). Both the heparinoid (OR 0.52, 95% CI 0.31 to 0.86, P = 0.01) and the LMWH (OR 0.56, 95% CI 0.44 to 0.73, P &lt; 0.00001) regimens were associated with lower incidence of DVT compared with UFH. </p> </section> <section id="CD000119-sec-0076"> <h4 class="title">Outcome analysis 1.6: PE during follow‐up</h4> <p>Six trials, involving 1250 participants (39.8% of the total number of participants), presented data on symptomatic PE. However, not all surviving participants had pulmonary ventilation scans because confirmation of PE was not sought systematically. Furthermore, not all participants who died had autopsies, which could lead to bias in the results. In addition, there were too few participants with PE to generate substantial evidence on whether or not the observed trend in favour of LMWH or heparinoid was significant or happened merely by chance (OR 0.57, 95% CI 0.23 to 1.41, I² = 0%; <a href="./references#CD000119-fig-0010" title="">Analysis 1.6</a>). In the published report of <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Turpie-1992" target="_blank">Turpie 1992</a>, no PEs were recorded, but unpublished data suggested a high possibility in one participant (who died but did not have an autopsy) in the UFH group. We excluded <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> from our analyses because data were only available for the treatment period and not the scheduled follow‐up period (PE occurring during the treatment in 1/666 enoxaparin versus 6/669 UFH participants, absolute risk difference –0.7%, 95% CI –1.5 to 0). </p> </section> <section id="CD000119-sec-0077"> <h4 class="title">Outcome analysis 1.7: Any intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period </h4> <p>Irresepctive of clinical deterioration, ideally an unbiased assessment of the effect of treatment on the occurrence of intracranial haemorrhage or haemorrhagic transformation of the infarct (HTI) would come from studies in which CT or MR scanning was performed systematically in all surviving participants at the beginning and end of the scheduled treatment period. However, the overall risk of intracranial haemorrhage may have been underestimated because it did not include those participants who may have died from an intracranial haemorrhage before a second scan could be performed and did not have an autopsy. The compromise of this scenario and the least biased and most fair assessment would be of the effect of treatment on the intracranial haemorrhage event or HTI detected by routine repeat CT scanning performed at the end of the scheduled treatment period in all survivors and by autopsy in all those who died during the treatment period (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#REF-Sandercock-1993" target="_blank">Sandercock 1993</a>). However, none of the included studies undertook this as a pre‐specified analysis. </p> <p>All trials also reported intracranial haemorrhage associated with clinical deterioration (symptomatic HTI) but this analysis could lead to bias, particularly if the trial was not double‐blind. In addition, the definition of deterioration varied between trials. 'Any HTI' was relatively uncommon (2.4% in all groups combined) and 'symptomatic HTI' was even more rare (0.9% in all groups combined). We may have underestimated the risk of any HTI somewhat because in <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hillbom-1998" target="_blank">Hillbom 1998</a> approximately 10% (20/212) of participants did not have a repeat CT scan and we assumed these participants did not have a haemorrhage. For this comparison (9 trials, 3137 participants) there was no significant difference in any HTI between LMWH or heparinoid and UFH (OR 0.75, 95% CI 0.46 to 1.23, P = 0.25, I² = 0%, low quality evidence; <a href="./references#CD000119-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD000119-sec-0078"> <h4 class="title">Outcome analysis 1.8: Symptomatic intracranial haemorrhage/haemorrhagic transformation of the infarct during treatment period </h4> <p>Data were available for eight trials (3102 participants). Overall, there was no significant difference in symptomatic HTI for LMWH or heparinoid versus UFH (OR 0.73, 95% CI 0.35 to 1.54, I² = 0%; <a href="./references#CD000119-fig-0012" title="">Analysis 1.8</a>). However, these analyses were based on very small numbers of events so the confidence intervals were very wide, implying that the available data were inadequate to provide reliable evidence on any possible excess risk of intracranial haemorrhage associated with LMWH or heparinoid compared with UFH. </p> </section> <section id="CD000119-sec-0079"> <h4 class="title">Outcome analysis 1.9: Extracranial haemorrhage during treatment period</h4> <p>Seven trials (3012 participants; 96% of included participants) reported data on extracranial haemorrhage during the treatment period. Only 14 major extracranial haemorrhages occurred (0.5% of all participants); this very low absolute risk of serious bleeding is probably related to the fact that participants considered to be at high risk of bleeding were excluded from the trials. LMWH or danaparoid were associated with a substantially higher risk of major extracranial bleeding than UFH (OR 3.79, 95% CI 1.30 to 11.06, I² = 0%; <a href="./references#CD000119-fig-0013" title="">Analysis 1.9</a>). </p> <p>Information on minor haemorrhages is probably less reliable because it was less systematically reported and definitions varied; for example, some trials reported minor bruising at the injection site whilst others did not. Minor extracranial haemorrhages were common (6.5% of all participants) and were mainly related to skin haematomas (formed by blood clots, and giving rise to a swelling under the skin) at the injection sites, mild haematemesis (vomiting of blood) in participants with nasogastric tubes, or mild haematuria (blood in urine) in participants with urinary catheters. There was no difference in minor bleeds in those participants allocated to LMWH or danaparoid compared with UFH (OR 0.91, 95% CI 0.67 to 1.24, I² = 0%). </p> </section> <section id="CD000119-sec-0080"> <h4 class="title">Outcome analysis 1.10: Effect of recurrent ischaemic stroke or recurrent stroke of unknown pathological type during treatment period </h4> <p>Two trials, <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a> and <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>, with 1839 participants, reported this outcome, which occurred in 8/923 participants allocated to LMWH or heparinoid versus 4/916 participants allocated to UFH; there was no evidence of a difference in this outcome between the two groups (OR 1.94, 95% CI 0.61 to 6.11, I² = 27%, low quality evidence; <a href="./references#CD000119-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD000119-sec-0081"> <h4 class="title">Indirect comparisons of different doses of heparinoid with standard heparin</h4> <p>Indirect comparisons suggested that 350 anti‐Xa units daily of danaparoid may be less effective at preventing DVT than 5000 IU of UFH twice daily (although the data were limited; <a href="./references#CD000119-fig-0015" title="">Analysis 1.11</a>). Although there were trends towards greater benefit in terms of DVT prevention with larger doses of danaparoid and with twice daily compared with once daily administration, these were not significant and were based on very few data. The data on the safety of different doses of danaparoid with regard to haemorrhages were also extremely limited although there was the suggestion that higher doses or twice daily administration may produce more haemorrhages than UFH (<a href="./references#CD000119-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD000119-sec-0082"> <h4 class="title">Sensitivity analyses</h4> <p>There was no evidence of a significant difference in any outcome between danaparoid and LMWH. The inclusion or exclusion of three trials as a result of their potentially inadequate allocation concealment did not materially affect the overall conclusions (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Hageluken-1992" target="_blank">Hageluken 1992</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-TRACE-2004" target="_blank">TRACE 2004</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Wong-2000" target="_blank">Wong 2000</a>). </p> </section> <section id="CD000119-sec-0083"> <h4 class="title">Publication bias</h4> <p>We performed a funnel plot analysis to determine whether an important number of small negative trials were missed as a form of publication bias. We generated funnel plots for two outcomes: death from all causes during the treatment period (<a href="#CD000119-fig-0004">Figure 4</a>), and death from all causes during follow‐up period (<a href="#CD000119-fig-0005">Figure 5</a>). These figures showed a degree of asymmetry, indicating possible publication bias, with under‐reporting of studies favouring UFH. However, it should be interpreted with caution due to the small number of studies, making the power of the test too low to distinguish chance from real asymmetry (<a href="./references#CD000119-bbs2-0047" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000119-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000119-sec-0084"></div> <p>It is not yet clear whether routine use of any anticoagulant treatment at all in acute stroke is beneficial (<a href="./references#CD000119-bbs2-0057" title="SandercockP , CounsellC , KaneEJ . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD000024] ">Sandercock 2015</a>), and so it is perhaps premature to start comparing different anticoagulant regimens. In contrast, aspirin has been shown to be effective in improving neurological outcomes and preventing pulmonary embolism (PE) following ischaemic stroke and carries little risk of major haemorrhage (<a href="./references#CD000119-bbs2-0056" title="SandercockP , CounsellC , TsengMC , CecconiE . Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD000029.pub3] ">Sandercock 2014</a>). </p> <section id="CD000119-sec-0085"> <h3 class="title" id="CD000119-sec-0085">Summary of main results</h3> <section id="CD000119-sec-0086"> <h4 class="title">Overall benefit of low‐molecular‐weight heparin (LMWH) or heparinoids versus unfractionated heparin (UFH) in acute ischaemic stroke </h4> <p>None of the included trials reported information on the primary outcome for this Cochrane Review update. Overall the included trials were at moderate risk of bias, and the quality of evidence for all outcomes assessed was low according to GRADE criteria. The analyses, which included only limited data on major clinical outcomes, suggested that, while LMWH or heparinoids may yield greater protection against deep vein thrombosis (DVT) than UFH, such benefits might be offset by an excess of intracranial haemorrhages and major extracranial haemorrhages, but the data on these potential risks in this update were inadequate. The numbers of deaths, intracranial haemorrhages, and major extracranial haemorrhages were small, and so the confidence intervals were wide and hence could not rule out significant harm from LMWH or heparinoids. </p> <p>For example, in <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a>, although the risk of venous thromboembolism (VTE) (symptomatic plus asymptomatic) was significantly lower among participants given LMWH, the study could not exclude a 69% increase in the risk of death up to day 14 and a 134% increase in the risk of intracranial haemorrhage with LMWH. This was because the event rates for these major clinical outcomes were low: PE and intracerebral haemorrhage occurred in 1% of participants respectively. It was challenging to conduct a trial large enough to assess the balance risk and benefit of the intervention with such low event rates. </p> </section> <section id="CD000119-sec-0087"> <h4 class="title">Prevention of DVT and PE in acute ischaemic stroke by LMWH or heparinoids versus UFH</h4> <p>As a whole, allocation to LMWH or heparinoid was associated with a significant reduction in DVT but the result was no longer statistically significant in the modified worst‐case scenario analysis. Many DVTs detected in stroke patients are clinically silent, and there is debate about the extent to which reductions in asymptomatic DVT correlate with reductions in clinically significant episodes of VTE (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#REF-Lowe-2003" target="_blank">Lowe 2003</a>). There were too few people with PE among the included trials to generate substantial evidence on whether or not the observed trend in favour of LMWH or heparinoid was merely by chance. </p> </section> <section id="CD000119-sec-0088"> <h4 class="title">Risk of intra‐ and extracranial haemorrhage in acute ischaemic stroke with LMWH or heparinoids versus UFH </h4> <p>Although there was no significant difference in intracranial haemorrhage between LMWH or heparinoid and UFH during treatment periods, in participants allocated to LMWH or heparinoid versus UFH, there was a statistically significant increase in major extracranial haemorrhages. However, there were only 14 major extracranial haemorrhages (0.5% of all participants). This very low absolute risk of serious bleeding was probably related to the fact that participants considered to be at high risk of bleeding were excluded from the trials. Information on minor haemorrhages should be interpreted cautiously because these events were systematically reported less frequently and definitions varied; for example, some trials reported minor bruising at the injection site but others did not. There was no difference in minor bleeds among participants allocated to LMWH or danaparoid compared with UFH. </p> </section> </section> <section id="CD000119-sec-0089"> <h3 class="title" id="CD000119-sec-0089">Overall completeness and applicability of evidence</h3> <p>Most included trials were conducted more than 10 years ago, which may raise concerns about whether these results are still relevant for current clinical practice. The management of people with acute ischaemic stroke in the past two decades has changed, especially where acute stroke units have been established that provide better general care, early rehydration and active mobilisation which may reduce VTE frequency. On the other hand, greater use of intravenous thrombolysis may increase the haemorrhagic risks of anticoagulation. However, these changes in background clinical care may be expected to alter the absolute risks of various outcomes, but not greatly alter the estimates of relative effect of anticoagulation. It is unclear whether these data remain relevant in current clinical practice. </p> </section> <section id="CD000119-sec-0090"> <h3 class="title" id="CD000119-sec-0090">Quality of the evidence</h3> <p>Five of nine included trials did not specify methods of random sequence generation, and eight did not specify how allocation concealment was achieved, leading to assessment of unclear risk of selection bias. Most included trials did not provide sufficient information to enable assessment of selective reporting, hence risk of reporting bias was assessed as unclear (<a href="#CD000119-fig-0003">Figure 3</a>). Overall, for each of the outcomes reported in our 'Summary of findings' table, the quality of evidence was graded as low. Furthermore, the largest trial, <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> (N = 1762), was unblinded, which may have led to performance bias that could potentially affect review findings. The funnel plot analysis included too few studies to provide reliable evidence of, or reliably to exclude, publication bias. </p> <p>This review does not reliably answer the question it set out to address: whether heparinoids or LMWHs are more effective, yet as safe as UFH to prevent neurological disability and VTE in people with acute ischaemic stroke. To provide guidance on which categories of people with ischaemic stroke may benefit from heparinoids or LMWHs, and more accurate and precise estimates of the risks of death and haemorrhage, much larger randomised controlled trials are required that compare danaparoid (or LMWHs) with UFH and with control in many thousands of participants. It is unlikely that any trial of this size could ever be performed. </p> </section> <section id="CD000119-sec-0091"> <h3 class="title" id="CD000119-sec-0091">Potential biases in the review process</h3> <p>Completeness of the searches: we are confident that the Cochrane Stroke Group Trials Register is an efficient and reliable way of identifying registered and ongoing trials relevant to this review. The extensive searches performed for the 2008 review and in 2015 for this update did not identify any major large‐scale studies that were underway at the time of searching. The Cochrane Stroke Group Trials Register was searched again in July 2016 before this update was submitted. However, given the large number of apparently randomised stroke trials reported in scant detail in hard‐to‐access literature in China, it is possible that some may have been eligible for inclusion. The reports we have been able to obtain from China (<a href="./references#CD000119-bbs2-0029" title="TanA . The application research on the treatment of acute ischemic stroke by using low molecular weight heparins and small dose of heparins. Journal of Medical Theory and Practice2002;15(11):1246‐7. ">Tan 2002</a>; <a href="./references#CD000119-bbs2-0032" title="WangZY , WangLC , ChenC , GenJY , GaoYS . A controlled study on the treatment of acute progressive cerebral infarction by continuous anticoagulation with small doses of heparin. Chinese Critical Care Medicine2012;24(5):290‐3. ">Wang 2012</a>; <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a>) were only available as abstracts and none clearly met our inclusion criteria. At least one trial was closed but never reported data (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Moulin-1994" target="_blank">Moulin 1994</a>), and another three are thought to be ongoing trials but no details were available (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508061438417848484830427744512%26format=REVMAN#STD-Aventis-2002" target="_blank">Aventis 2002</a>; <a href="./references#CD000119-bbs2-0018" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , Turcanova‐KoprusakovaM , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke – pilot study. Biomedical Papers2016;160(4):543‐8. NCT01862978 . Safety and efficacy of heparin and nadroparin in the acute phase of ischaemic stroke (Heparinas). clinicaltrials.gov/ct2/show/NCT01862978 (first received 20 May 2013). ">Heparinas 2013</a>; <a href="./references#CD000119-bbs2-0035" title="YoungWD , SmytheLG . Low‐molecular‐weight heparin (enoxaparin) in anticoagulation transition to oral warfarin in ischaemic cerebral vascular accident (CVA) or transient ischaemic attack (TIA) patients. ASHP Midyear Clinical Meeting. 2001; Vol. 36:496E. ">Young 2001</a>). The changes to the protocol between the previous version and this update were minor and could not have introduced bias, since no data were available for our primary outcome. </p> </section> <section id="CD000119-sec-0092"> <h3 class="title" id="CD000119-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>A non‐Cochrane review of LMWH versus UFH in people with ischaemic stroke supported the use of LMWH, due to the benefit of reducing venous thromboembolism (<a href="./references#CD000119-bbs2-0058" title="ShorrAF , JacksonWL , ShernerJH , MooresLK . Differences between low‐molecular weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a meta‐analysis. Chest2008;133(1):149‐55. ">Shorr 2008</a>). The study reported that there were no statistically significant increases in haemorrhage or death compared with UFH. However, a more recent and comprehensive review of heparin for DVT prophylaxis in medical patients found that in hospitalised medical patients (including those with stroke), heparin prophylaxis had no significant effect on mortality, may have reduced PE in medical patients and all patients combined, and led to more bleeding and major bleeding events, thus resulting in little or no net benefit (<a href="./references#CD000119-bbs2-0050" title="LederleFA , ZyllaD , MacDonaldR , WiltTJ . Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2011;155(9):602‐15. ">Lederle 2011</a>). </p> <section id="CD000119-sec-0093"> <h4 class="title">What is new in this update?</h4> <p>For this update, the main searches were performed up to February 2017. We identified no new studies that met review inclusion criteria. We identified a report of a sub‐analysis of the <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> trial published in 2009 that contained limited additional outcome data which were subsequently included in this updated review. However, the overall results and conclusions remained the same as 2008 (<a href="./references#CD000119-bbs2-0064" title="SandercockPAG , CounsellC , TsengM‐C . Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD000119.pub3] ">Sandercock 2008</a>). In previous versions of this review, outcomes were not divided into primary or secondary outcomes. In this updated review, the primary outcome was identified as the proportion dead or dependent in activities in daily living. We added more detailed assessment of risk of bias, funnel plots to assess for publication bias and a summary of findings table. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000119-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD000119-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000119-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000119-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during treatment period" data-id="CD000119-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during follow‐up" data-id="CD000119-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, outcome: death from all causes during follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 2 Death from all causes during treatment period." data-id="CD000119-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 2 Death from all causes during treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 3 Death from all causes during follow‐up." data-id="CD000119-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 3 Death from all causes during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 4 Vascular death during follow‐up." data-id="CD000119-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 4 Vascular death during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 5 Deep venous thrombosis during treatment period." data-id="CD000119-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 5 Deep venous thrombosis during treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 6 Pulmonary embolism during follow‐up." data-id="CD000119-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 6 Pulmonary embolism during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 7 Any intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period." data-id="CD000119-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 7 Any intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 8 Symptomatic intracranial haemorrhage/haemorrhagic transformation of the infarct during treatment period." data-id="CD000119-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 8 Symptomatic intracranial haemorrhage/haemorrhagic transformation of the infarct during treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 9 Extracranial haemorrhage during treatment period." data-id="CD000119-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 9 Extracranial haemorrhage during treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 10 Effect of recurrent ischaemic stroke or recurrent stroke of unknown pathological type during treatment period." data-id="CD000119-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 10 Effect of recurrent ischaemic stroke or recurrent stroke of unknown pathological type during treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 11 Deep venous thrombosis according to heparinoid dosage regimen." data-id="CD000119-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 11 Deep venous thrombosis according to heparinoid dosage regimen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000119-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/urn:x-wiley:14651858:media:CD000119:CD000119-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_t/tCD000119-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 12 Intracranial and extracranial haemorrhage during treatment according to dosage regimen." data-id="CD000119-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 LMWH/heparinoid versus standard UFH in acute ischaemic stroke, Outcome 12 Intracranial and extracranial haemorrhage during treatment according to dosage regimen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/media/CDSR/CD000119/image_n/nCD000119-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000119-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Low‐molecular‐weight heparins or heparinoids compared with unfractionated heparin for acute ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐molecular‐weight heparins (LMWH) or heparinoids compared with unfractionated heparin (UFH) for acute ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute ischaemic stroke<br/> <b>Setting:</b> patients admitted to hospital with stroke of sufficient severity to cause immobility<br/> <b>Intervention:</b> LMWH/heparinoids<br/> <b>Comparison:</b> UFH </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with UFH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH/heparinoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Death from all causes during treatment</b> (range 6 days to 16 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 1.06<br/> (0.78 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3102<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/> (72 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000<br/> (105 to 180) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Death from all causes during follow up</b> (range 2 weeks to 12 weeks) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.98<br/> (0.79 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3102<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/> (187 to 263) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/> (209 to 292) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Deep vein thrombosis during treatment period</b> (range 6 days to 16 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.55<br/> (0.44 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2585<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000⁶</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000<br/> (93 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (105 to 158) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Pulmonary embolism during treatment period</b> (range 6 days to 16 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.57<br/> (0.23 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1250<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ⁷ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 7) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000⁴</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/> (6 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period</b> (range 6 days to 16 days)⁹ </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.73<br/> (0.35 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3102<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹ ⁸ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000³</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (4 to 18) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>RCT</b> : randomised controlled trial; <b>LWMH</b> : low‐molecular‐weight heparin; <b>UFH</b>: unfractionated heparin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ There were unclear risk of selection bias in <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a>, <a href="./references#CD000119-bbs2-0001" title="DumasR , WoitinasF , KutnowskiM , NikolicI , BerberichR , AbedinpourF , et al. A multi‐centre double blind randomized study to compare the safety and efficacy of once‐daily ORG 10172 and twice‐daily low‐dose heparin in preventing deep‐vein thrombosis in patients with acute ischaemic stroke. Age and Ageing1994;23(6):512‐6. HagelukenC , EgbertsJ , StiekemaJ . A multi‐centre, assessor‐blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non‐haemorrhagic stroke of recent onset (protocol 87038). Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands1992. ">Dumas 1994</a>, <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a>, <a href="./references#CD000119-bbs2-0007" title="WoessnerR , GrauerM , BianchiO , MuellerM , MoersdorfS , BerlitP , et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis2004;91(4):690‐3. ">TRACE 2004</a>, <a href="./references#CD000119-bbs2-0008" title="MagnaniHN , EgbertsJFM . A preliminary report of a multi‐centre, assessor‐blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004‐010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands1992. TurpieAGG . Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis1992;22(2):92‐8. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1991;65:753. TurpieAGG , LevineMN , PowersPJ , GinsbergJG , JayRM , KlimekM , et al. A low‐molecular‐weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine1992;117(5):353‐7. ">Turpie 1992</a> and <a href="./references#CD000119-bbs2-0009" title="WongWJ , LoYK , HuHH . Comparison of subcutaneous low‐molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases2000;9(Suppl 1):183‐4. ">Wong 2000</a>. <a href="./references#CD000119-bbs2-0002" title="HagelukenC , EgbertsJ . A multi‐centre, assessor‐blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non‐haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands1992. ">Hageluken 1992</a> and <a href="./references#CD000119-bbs2-0006" title="HossmanV , LoettgenJ , AuelH , BewermeyerH , HeissWD . Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double‐blind study. Haemostasis1986;16(Suppl 5):54. StiekemaJCJ , EgbertsJFM , VoermanJ . An open, randomised, pilot multi‐centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non‐haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands1988. ">Stiekema 1988</a> were single blinded studies; <a href="./references#CD000119-bbs2-0004" title="KaseCS , AlbersGW , BladinC , FieschiC , GabbaiAA , O'RiordanW , et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke2009;40(11):3532‐40. [DOI: 10.1161/STROKEAHA.109.555003] ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open‐label randomised comparison. Lancet2007;369(9570):1347‐55. ">PREVAIL 2007</a> was an open label study. Hence, making all these study high risk of performance and detection bias (downgraded 1 level). </p> <p>² Small number of deaths were recorded throughout studies (downgraded 1 level).</p> <p>³ Calculated based on control event rate from <a href="./references#CD000119-bbs2-0049" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569‐81. ">IST 1997</a> where based on the inclusion criteria, it was interpreted that people are of average risk (hence, they are classified as 'moderate risk population') of developing complications such as deep vein thrombosis (DVT), pulmonary embolism (PE), cranial haemorrhages etc. that resulted in death or disability. </p> <p>⁴ Calculated based on control event rate from <a href="./references#CD000119-bbs2-0042" title="DennisM , SandercockP , GrahamC , ForbesJ , Clots Trials Collaboration. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post‐stroke deep vein thrombosis and to estimate its cost‐effectiveness. Health Technology Assessment2015;19(76):1‐90. [DOI: 10.3310/hta19760] ">CLOTS3 2015</a> trial where based on the inclusion criteria, people are of high risk (hence they are classified as 'high risk population') of developing complications such as DVT, PE, cranial haemorrhages that resulted in death or disability. </p> <p>⁵ Methods of detection of detection of DVT were variable across the studies (downgraded 1 level). </p> <p>⁶ Calculated based on mean baseline risk from the studies of this Cochrane Review because <a href="./references#CD000119-bbs2-0049" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569‐81. ">IST 1997</a> did not include this outcome data. </p> <p>⁷ Small number of PEs across the studies.</p> <p>⁸ Small number of symptomatic intracranial haemorrhage across studies.</p> <p>⁹ High risk population not available as <a href="./references#CD000119-bbs2-0042" title="DennisM , SandercockP , GrahamC , ForbesJ , Clots Trials Collaboration. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post‐stroke deep vein thrombosis and to estimate its cost‐effectiveness. Health Technology Assessment2015;19(76):1‐90. [DOI: 10.3310/hta19760] ">CLOTS3 2015</a> trial did not include this outcome data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Low‐molecular‐weight heparins or heparinoids compared with unfractionated heparin for acute ischaemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/full#CD000119-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000119-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LMWH/heparinoid versus standard UFH in acute ischaemic stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1 Dead or dependent at the end of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death from all causes during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.78, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Heparinoid versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.62, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 LMWH versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.72, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Death from all causes during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.79, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Heparinoid versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.69, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 LMWH versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Vascular death during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.72, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Heparinoid versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.68, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 LMWH versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.39, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Deep venous thrombosis during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.44, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Heparinoid versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 LMWH versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.44, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pulmonary embolism during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.23, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Heparinoid versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.18, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 LMWH versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.13, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Any intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.46, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Heparinoid versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.43, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 LMWH versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.37, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Symptomatic intracranial haemorrhage/haemorrhagic transformation of the infarct during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.35, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Heparinoid versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.19, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 LMWH versus standard UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.30, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Extracranial haemorrhage during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Major extracranial haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.79 [1.30, 11.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Minor extracranial haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.67, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Effect of recurrent ischaemic stroke or recurrent stroke of unknown pathological type during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.61, 6.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 LMWH versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.61, 6.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Deep venous thrombosis according to heparinoid dosage regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 350 anti‐Xa units 24‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.67, 6.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 750 anti‐Xa units 24‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.14, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 1250 anti‐Xa units 24‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.32, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 750 anti‐Xa units 12‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.13, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 1250 anti‐Xa units 12‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.06, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Intracranial and extracranial haemorrhage during treatment according to dosage regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 350 anti‐Xa units 24‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.45, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 750 anti‐Xa units 24‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.33, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 1250 anti‐Xa units 24‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 750 anti‐Xa units 12‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [1.03, 7.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 1250 anti‐Xa units 12‐hourly versus 5000 IU UFH 12‐hourly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.31, 9.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LMWH/heparinoid versus standard UFH in acute ischaemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000119.pub4/references#CD000119-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000119.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000119-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000119-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000119-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000119-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD000119-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD000119-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD000119-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="ta#CD000119-note-0005">தமிழ்</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000119-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000119\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000119\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000119\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000119\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000119\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000119.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000119.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000119.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000119.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000119.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715634359"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000119.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715634363"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000119.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8be4c9179371',t:'MTc0MDcxNTYzNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 